| Authors: |
Christie CF; Neuroene Therapeutics, Kensington, MD 20895, USA., Bendell E; Neuroene Therapeutics, Kensington, MD 20895, USA., Renaud L; Neuroene Therapeutics, Kensington, MD 20895, USA; Medical University of South Carolina, Charleston, South Carolina 29425, USA., Williamson T; Medical University of South Carolina, Charleston, South Carolina 29425, USA., Li X; Medical University of South Carolina, Charleston, South Carolina 29425, USA., Himes RA; Neuroene Therapeutics, Kensington, MD 20895, USA., Prosser LC; Medical University of South Carolina, Charleston, South Carolina 29425, USA., Edwards SF; Anticonvulsant Drug Development (ADD) Program, Department of Pharmacology & Toxicology, University of Utah, 84112, USA., Metcalf CS; Anticonvulsant Drug Development (ADD) Program, Department of Pharmacology & Toxicology, University of Utah, 84112, USA., West PJ; Anticonvulsant Drug Development (ADD) Program, Department of Pharmacology & Toxicology, University of Utah, 84112, USA., Wilcox KS; Anticonvulsant Drug Development (ADD) Program, Department of Pharmacology & Toxicology, University of Utah, 84112, USA., James Chou C; Neuroene Therapeutics, Kensington, MD 20895, USA; Medical University of South Carolina, Charleston, South Carolina 29425, USA. Electronic address: james@neuroenetherapeutics.com., Chan SSL; Neuroene Therapeutics, Kensington, MD 20895, USA; Medical University of South Carolina, Charleston, South Carolina 29425, USA. Electronic address: sherine@neuroenetherapeutics.com. |
